Impact of high-dose atorvastatin in coronary heart disease patients age 65 to 78 years

Clinical Cardiology

Volumn 32, Issue 5, 2009, Pages 256-263

  Koren, Michael J ^a,d   Feldman, Theodore ^b   Mendes, Robert A ^c  

^a Jacksonville Center for Clinical Research   (United States)

^b MIAMI RESEARCH ASSOCIATES   (United States)

^c PFIZER INC   (United States)

^d Jacksonville Center for Clinical Research   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

AGED; AGING; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; DYSLIPIDEMIA; FEMALE; FOLLOW UP; HEART DEATH; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MYOPATHY; RHABDOMYOLYSIS; RISK REDUCTION; SIDE EFFECT;

AGE FACTORS; AGED; ANTICHOLESTEREMIC AGENTS; CHOLESTEROL, LDL; CONFIDENCE INTERVALS; CORONARY ARTERY DISEASE; FEMALE; HEPTANOIC ACIDS; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PYRROLES; RISK;

EID: 66249107423     PISSN: 01609289     EISSN: None     Source Type: Journal    
DOI: 10.1002/clc.20448     Document Type: Article

References (15)

1. Thom T, Haase N, Rosamond W, Howard VJ, Rumsfeld J, et al.: Heart disease and stroke statistics-2006 update: A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2006;113:e85-e151. (Pubitemid 43754289)
2. Muntner P, Garrett E, Klag MJ, Coresh J: Trends in stroke prevalence between 1973 and 1991 in the US population 25 to 74 years of age. Stroke. 2002;33:1209-1213.
3. Kochanek KD, Murphy SL, Anderson RN, Scott C: Deaths: Final data for 2002. Natl Vital Stat Rep. 2004;53:1-115.
4. Hunt D, Young P, Simes J, Hague W, Mann S, et al.: Benefits of pravastatin on cardiovascular events andmortality in older patients with coronary heart disease are equal to or exceed those seen in younger patients: Results from the LIPID trial. Ann Intern Med. 2001;134:931-940. (Pubitemid 32466232)
5. Miettinen TA, Pyorala K, Olsson AG, Musliner TA, Cook TJ, et al.: Cholesterol-lowering therapy in women and elderly patients with myocardial infarction or angina pectoris: Findings from the Scandinavian Simvastatin Survival Study (4S). Circulation. 1997;96:4211-4218. (Pubitemid 28007446)
6. Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, et al.: Pravastatin in elderly individuals at risk of vascular disease (PROSPER): A randomised controlled trial. Lancet. 2002;360:1623-1630. (Pubitemid 35379733)
7. Deedwania P, Stone PH, Bairey Merz CN, Cosin-Aguilar J, Koylan N, et al.: Effects of intensive versusmoderate lipid-lowering therapy on myocardial ischemia in older patients with coronary heart disease: Results of the Study Assessing Goals in the Elderly (SAGE). Circulation. 2007;115:700-707. (Pubitemid 46294760)
8. Allen Maycock CA, Muhlestein JB, Horne BD, Carlquist JF, Bair TL, et al.: Statin therapy is associated with reduced mortality across all age groups of individuals with significant coronary disease, including very elderly patients. J Am Coll Cardiol. 2002;40:1777-1785. (Pubitemid 35341956)
9. Wenger NK, Lewis SJ, Herrington DM, Bittner V, Welty FK: Outcomes of using high- or low-dose atorvastatin in patients 65 years of age or older with stable coronary heart disease. Ann Intern Med. 2007;147:1-9.
10. Koren MJ, Hunninghake DB: Clinical outcomes in managed-care patients with coronary heart disease treated aggressively in lipid-lowering diseasemanagement clinics: The ALLIANCE study. J Am Coll Cardiol. 2004;44:1772-1779. (Pubitemid 39424074)
11. Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, et al.: Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004;110:227-239. (Pubitemid 38924592)
12. Pearson TA, Laurora I, Chu H, Kafonek S: The lipid treatment assessment project (L-TAP): A multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med. 2000;160:459-467. (Pubitemid 30112269)
13. Sever PS, Dahlof B, Poulter NR, Wedel H, Beevers G, et al.: Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): A multicentre randomised controlled trial. Lancet. 2003;361:1149-1158. (Pubitemid 36398384)
14. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, et al.: Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): Multicentre randomised placebo-controlled trial. Lancet. 2004;364:685-696. (Pubitemid 39140624)
15. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, et al.: Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350:1495-1504. (Pubitemid 38477774)